
AI pioneer Innoplexus and phytopharmaceutical company DrD are partnering toRead More
AI pioneer Innoplexus and phytopharmaceutical company DrD are partnering toRead More
Jun 23
Feb 23
Innoplexus wins Horizon Interactive Gold Award for Curia App
Read MoreExciting News! Anavex Life Sciences and Partex NV Announce Strategic Partnership to Enhance Patient Experience.
Anavex Life Sciences Corp. and Partex NV N.V. Group are pleased to announce their strategic partnership, aimed at revolutionizing the biopharma industry. By leveraging Partex’s proprietary AI (Artificial Intelligence) technology and Anavex’s innovative precision medicine drug development platform, we seek to enhance patient outcomes and reshape the future of healthcare.
Dr. Gunjan Bhardwaj, CEO of Partex NV, expressed his excitement, stating, “Together with Anavex, we embark on this impactful journey to extend our patient ecosystem. Our Life Sciences Language Processing platform with Generative Artificial Intelligence capabilities will significantly improve patient outcomes.”
Dr. Christopher Missling, PhD, President and CEO of Anavex Life Sciences, added, “We are thrilled to collaborate with Partex and fully embrace AI to expand beyond R&D into healthcare sales marketing. Our expertise in precision medicine drug development, combined with Partex’s disruptive approach, will bring better treatment options to patients in a truly patient-centric manner.”
Stay tuned for the groundbreaking advancements we’ll achieve together. Together, we are reshaping the future of biopharma.
Exciting News! Anavex Life Sciences and Partex NV Announce Strategic Partnership to Enhance Patient Experience.Anavex Life Sciences Corp. and Partex NV N.V. Group are pleased to announce…
The treatment and support of patients with advanced tumor diseases is a complex task involving numerous disciplines. For the interdisciplinary…
Artificial Intelligence (AI) pioneer Innoplexus and London based Parametric Insurance start-up, Innovatrix Capital, collaborating upon using AI & Machine Learning…
Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial Intelligence to expedite PIM kinase inhibitor development ESCHBORN, Germany, May 30,…
COVID-19 Clearinghouse enables direct access to latest COVID-19 datasets, publications, research and clinical trialsBOSTON and DURHAM, N.C. and ESCHBORN, Germany,…
Das Eschborner Unternehmen Innoplexus hat eine neue App namens „Curia“ für Krebspatienten veröffentlicht. Mit dem Computerprogramm, das sich unentgeltlich herunterladen…
Frankfurt, Germany, March 26, 2020 — Innoplexus AG has been honored with the Silver Edison Award 2020 for its proprietary…
While drug development can be incredibly lucrative, it is a very risky business. German company Innoplexus has developed a domain-specific…
Successful clinical trials occur at a ratio of 1 in 10, costing around $2-$3 billion, with drugs taking 10–12 years…
If your loved one was diagnosed with a potentially fatal illness, wouldn’t you want all the information possible to be…